The Analyst Verdict: Artivion In The Eyes Of 4 Experts
4 analysts have expressed a variety of opinions on Artivion (NYSE:AORT) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $55.0, along with a high estimate of $58.00 and a low estimate of $51.00. Witnessing a positive shift, the current average has risen by 7.32% from the previous average price target of $51.25.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Artivion among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Buy | $58.00 | $58.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $51.00 | $50.00 |
| Daniel Stauder | Citizens | Raises | Market Outperform | $53.00 | $47.00 |
| Mike Matson | Needham | Raises | Buy | $58.00 | $50.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Artivion. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Artivion compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Artivion's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Artivion's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Artivion analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Financial Insights: Artivion
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Artivion displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 18.39%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Artivion's net margin is impressive, surpassing industry averages. With a net margin of 5.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Artivion's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.51% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Artivion's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.77% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.6.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.